Expert and Patient Perspectives on AE Management With FGFR Inhibitors in Cholangiocarcinoma

Goyal, Bishop, Kelley, and Kuhlman discuss ways to prepare patients with cholangiocarcinoma for FGFR inhibitor–related adverse effects.

Related Keywords

Massachusetts ,United States ,Boston ,California ,Lipika Goyal ,Chaundra Bishop ,Caroline Kulhman ,Katie Kelley ,Ashling Wahner ,Cancer Immunotherapy Program ,Department Of Medicine Hematology Oncology ,Taiho Pharmaceutical Co Ltd ,Facebook ,Linkedin ,University Medical Line At Stanford Medicine ,Twitter ,Live On Air ,University Medical Line ,Stanford Medicine ,Massachusetts General Hospital ,Onclive On Air ,Apple Podcasts ,Google Podcasts ,Amazon Music ,D ,The University Of California San Francisco Helen Diller Family Comprehensive Cancer Center ,P ,Patients With Cholangiocarcinoma ,Fgfr Inhibitor Related Adverse Effects ,